DexCom (DXCM)
(Delayed Data from NSDQ)
$65.68 USD
-1.42 (-2.12%)
Updated Oct 3, 2024 04:00 PM ET
After-Market: $65.69 +0.01 (0.02%) 7:58 PM ET
3-Hold of 5 3
C Value B Growth D Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$65.68 USD
-1.42 (-2.12%)
Updated Oct 3, 2024 04:00 PM ET
After-Market: $65.69 +0.01 (0.02%) 7:58 PM ET
3-Hold of 5 3
C Value B Growth D Momentum C VGM
Zacks News
Shockwave Medical (SWAV) Q3 Earnings Beat, Revenues Rise Y/Y
by Zacks Equity Research
Shockwave Medical's (SWAV) third-quarter results reflect robust revenue growth and gross margin expansion on the back of strong demand and new launches.
Insulet (PODD) Banks on Omnipod for Consistent Market Share Gain
by Zacks Equity Research
Insulet's (PODD) Omnipod 5 continues to be a driving force behind U.S. and international growth.
QIAGEN (QGEN) Launches Workflow to Boost Microbiome Research
by Zacks Equity Research
QIAGEN (QGEN) expands the Microbiome solutions portfolio with the launch of Microbiome WGS SeqSets.
Here's Why You Should Retain Tandem Diabetes (TNDM) Now
by Zacks Equity Research
Investors remain optimistic about Tandem Diabetes (TNDM), backed by upcoming innovative launches, including Mobi and the new integrated CGM offering.
QIAGEN's (QGEN) Molecular Diagnostics Gains Share, FX Woe Stays
by Zacks Equity Research
QIAGEN (QGEN) continues to see a very healthy conversion trend from the tuberculin skin test.
Bruker (BRKR) Q3 Earnings and Revenues Top, '23 Sales View Up
by Zacks Equity Research
Bruker (BRKR) delivers better-than-expected earnings and revenues in the third quarter of 2023.
Inari Medical (NARI) Q3 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Inari Medical's (NARI) third-quarter results benefit from strong product adoption and geographical performances.
AMN Healthcare (AMN) Q3 Earnings and Revenues Beat Estimates
by Zacks Equity Research
AMN Healthcare's (AMN) dismal results in all its segments led to a soft overall third-quarter performance.
Cardinal Health (CAH) Beats on Q1 Earnings, Ups '24 EPS View
by Zacks Equity Research
Cardinal Health's (CAH) first-quarter fiscal 2024 results benefit from the Pharmaceutical segment's solid performance.
Stryker (SYK) Q3 Earnings Beat on Strong Segmental Result
by Zacks Equity Research
Stryker's (SYK) third-quarter earnings reflect strong performance across its segments and geographies. However, unfavorable currency movement hurts sales growth, and rising costs affect margins.
Fresenius Medical (FMS) Q3 Earnings Miss, Operating Margin Up
by Zacks Equity Research
Fresenius Medical's (FMS) third-quarter revenues suffer due to unfavorable currency movement. However, the company's transformational plans continue to benefit its operating income.
Prestige Consumer (PBH) Q2 Revenues Top, Margins Expand
by Zacks Equity Research
Prestige Consumer's (PBH) second-quarter fiscal 2024 results benefit from a diverse brand portfolio and broad distribution.
Omnicell (OMCL) Q3 Earnings and Revenues Beat, Margins Down
by Zacks Equity Research
Omnicell's (OMCL) third-quarter 2023 results reflect operational discipline in a weak demand environment.
Avanos (AVNS) Q3 Earnings Top Estimates, Margins Contract
by Zacks Equity Research
Despite strength in Avanos' (AVNS) Digestive Health segment, its overall third-quarter results reflect soft performances.
QuidelOrtho (QDEL) Q3 Earnings Top Estimates, Margins Down
by Zacks Equity Research
Despite solid performances by the Labs and TM segments and China and Other regions, QuidelOrtho (QDEL) reports soft overall top-line results in third-quarter 2023.
Why DexCom (DXCM) Might be Well Poised for a Surge
by Zacks Equity Research
DexCom (DXCM) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Nevro (NVRO) Q3 Earnings Top Estimates, FY23 Revenue View Up
by Zacks Equity Research
Nevro's (NVRO) worldwide revenues improve on a year-over-year basis in the third quarter, owing to robust domestic performance.
Cencora (COR) Q4 Earnings Top, GLP-1 Drugs Boost Sales
by Zacks Equity Research
Cencora's (COR) fourth-quarter fiscal 2023 results benefit from overall market growth, including rising demand for GLP-1 drugs approved for diabetes and weight loss. Inflationary pressure remains.
Baxter (BAX) Beats on Q3 Earnings, Divests BioPharma Business
by Zacks Equity Research
Baxter (BAX) reports better-than-expected third-quarter earnings and sales. The company completes the divestment of its BioPharma Solution business. It starts reporting under a new operating model.
DENTSPLY SIRONA (XRAY) Beats on Q3 Earnings, Lowers '23 Guidance
by Zacks Equity Research
DENTSPLY SIRONA's (XRAY) Q3 revenues are driven by a rise in demand for aligners and CAD/CAM in the United States and a recovery in demand in China. Challenging macro headwinds linger.
Glaukos (GKOS) Q3 Earnings Beat Estimates, Revenues Rise Y/Y
by Zacks Equity Research
Glaukos' (GKOS) third-quarter revenues beat estimates but fall year over year. Sales and gross margin improve, while higher operating expenses lead to a wider operating loss.
McKesson (MCK) Beats on Q2 Earnings, Raises '23 EPS View
by Zacks Equity Research
McKesson's (MCK) second-quarter fiscal 2024 results benefit from growth in the United States. Divestment hurts the International segment.
Wall Street Analysts Think DexCom (DXCM) Could Surge 36.81%: Read This Before Placing a Bet
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 36.8% in DexCom (DXCM). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
DexCom (DXCM) Just Reclaimed the 50-Day Moving Average
by Zacks Equity Research
Good things could be on the horizon when a stock surpasses the 50-Day simple moving average. How should investors react?
Tandem Diabetes (TNDM) Posts Wider Q3 Loss, Trims '23 Sales View
by Zacks Equity Research
Tandem Diabetes (TNDM) reports a higher-than-anticipated loss in the third quarter of 2023.